Streetbeat News

Stock Prices

NOW

The options market shows a bullish sentiment towards ServiceNow (NYSE:NOW), with 64% of traders favoring calls over puts. The price target is between $600 and $920, with significant trading activity in this range. Despite a recent 3.35% price drop, the consensus target price remains at $900. An analyst from Needham has lowered the rating to Buy with a $900 target.

Portfolio Pulse from Benzinga Insights

September 25, 2024 | 1:46 pm

NNDM

Trading for a certain asset was halted at 9:40:28 a.m. ET due to pending news. This indicates that significant information is expected to be released, which could impact the asset's price once trading resumes.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:40 pm

MKFG

Markforged shares have been halted pending news, indicating a significant announcement or event that could impact the company's stock price.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:36 pm

CERO

CERo Therapeutics shares rose following the announcement of $1.25 million in financing and a request for an FDA type A meeting to address the clinical hold on CER-1236.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:36 pm

HRTS

NVO

Novo Nordisk is facing political pressure over high U.S. prices for its weight-loss drugs, Ozempic and Wegovy, as the U.S. presidential election approaches. The company's CEO testified before Congress, attributing pricing issues to pharmacy benefit managers (PBMs). Despite potential price cuts, demand for these drugs remains strong, and Novo Nordisk's U.S. revenues are expected to remain stable. The political focus on drug pricing is bipartisan, and increased M&A activity in the pharmaceutical sector is anticipated post-election.

Portfolio Pulse from Piero Cingari

September 25, 2024 | 1:35 pm

ORAN

QTUM

Orange plans to delist its ADRs from the NYSE to reduce financial burdens, while maintaining its U.S. presence and investor communication. The delisting will occur in Q4 2024, with ADRs trading on the OTC market thereafter. Orange remains committed to its U.S. operations and partnerships.

Portfolio Pulse from Lekha Gupta

September 25, 2024 | 1:34 pm

BXSL

Blackstone Secured Lending Fund has filed with the SEC to issue and sell common shares worth up to $500 million. This move could impact the company's stock price and investor sentiment.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:34 pm

ACST

Acasti Pharma's shares rose following the announcement of completing patient enrollment for its Phase 3 strive-on safety trial.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:33 pm

WINT

Windtree Therapeutics announced positive Phase 2b study results for its heart failure drug candidate, istaroxime, which improved systolic blood pressure in patients with early cardiogenic shock. The drug showed significant benefits in primary and secondary endpoints with a favorable safety profile. Despite the positive news, WINT stock is down 7.98% in premarket trading.

Portfolio Pulse from Vandana Singh

September 25, 2024 | 1:33 pm

ENTX

Entera Bio shares rose following positive results from their obesity and metabolic disorder studies, indicating significant systemic exposure and a favorable pharmacokinetic profile.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:31 pm